Molecularly Targeted Radionuclide Therapy for Metastatic Non-Small Cell Lung Cancer
This study is testing a new approach for metastatic non-small cell lung cancer (NSCLC), which is a type of lung cancer that has spread. It uses two related substances: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. First, you would have a special scan ([68Ga]Ga DOTA-5G PET/CT) to see if your cancer lights up with the first substance. If it does, you might then receive the treatment ([177Lu]Lu DOTA-ABM-5G). This is a Phase 1 study, meaning it's focused on checking the safety and how well these substances are tolerated, as well as looking for signs of effectiveness. The study aims to enroll up to 40 participants and is currently recruiting.
- Study design
- This is a Phase 1 interventional study, meaning all participants will receive the study interventions. It plans to enroll up to 40 participants.
- What's involved
- You would undergo a [68Ga]Ga DOTA-5G PET/CT scan. If eligible, you would then receive [177Lu]Lu DOTA-ABM-5G therapy.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your response to treatment will be measured at 30 days and 60 days after receiving [177Lu]Lu DOTA-ABM-5G.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Julie L Sutcliffe, PhD · PRINCIPAL_INVESTIGATOR · University of California, Davis
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- [68Ga]Ga DOTA-5G PET/CT imaging2 hours from time of injection
To assess the ability of \[68Ga\]Ga DOTA-5G to detect lesions in patients with metastatic NSCLC
- [177Lu]Lu DOTA-ABM-5G treatment30 days from time of treatment
To assess the safety and tolerability of a single treatment with \[177Lu\]Lu DOTA-ABM-5G
- [177Lu]Lu DOTA-ABM-5G treatment efficacy60 days from time of treatment
To assess treatment efficacy (response vs. no response) assessed by comparison with a post-treatment scan (standard of care imaging and post second \[68Ga\]Ga DOTA-5G PET/CT, prior to next line of therapy.